HealthDay News — Conditions offering alternative explanations for lung cancer symptoms are associated with increased diagnostic intervals, according to a study published online Aug. 23 in the British ...
A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors.
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
A novel CAR T-cell therapy, GCC19CART, has demonstrated activity in patients with heavily pretreated, metastatic colorectal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback